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A B S T R A C T
Background: QuantiFERON (QFT) results near the cut-off are subject to debate. We aimed to investigate which
borderline QFT results were due to Mycobacterium tuberculosis (Mtb)-specific responses or to test variability.
Methods: In a contact investigation, tuberculin skin test (TST), QFT and T-SPOT.TB (T-SPOT) were performed in
785 BCG-unvaccinated contacts. Contacts with a low-negative (< 0.15), borderline (0.15–0.35), low-positive
(0.35–0.70) or high-positive QFT (≥0.70 IU/mL) were compared with respect to exposure, TST and T-SPOT
results. Development of active tuberculosis was assessed.
Results: Borderline QFT results occurred in threefold excess over test variability (p=0.0027). In contacts with
low-negative, borderline or positive QFT results, a positive TST occurred in 24.9%, 62.1% and 91.4%
(p < 0.0001) and a positive T-SPOT result in 6.3%, 41.3% and 86.4%, respectively (p < 0.0001). Two-third
(20/29) of contacts with a borderline and 14/16 (88%) with a low-positive QFT had a positive TST and/or T-
SPOT, indicating probable Mtb-infection. During 12 years of follow-up, seven patients were diagnosed with
active tuberculosis, two of whom after a low-positive QFT.
Conclusions: In this study, most borderline and low-positive QFT results were Mtb-specific, showing the biolo-
gical significance of a borderline QFT. The clinical relevance, however, will be most distinct in patients who are
or will be immunocompromised.
1. Introduction
Interferon-gamma release assays (IGRAs) measure Mycobacterium
tuberculosis (Mtb) specific responses and are mainly used for the eva-
luation of latent tuberculosis infection (LTBI). Commercially available
IGRAs are not affected by prior Mycobacterium bovis bacillus Calmette-
Guérin (BCG) vaccination, which is an important advantage compared
to the tuberculin skin test (TST) [1,2]. Commercial IGRAs are T-
SPOT.TB (T-SPOT) (Oxford Immunotec, Abingdon, UK) which measures
the number of interferon-γ (IFN-γ) producing peripheral blood mono-
nuclear cells, and QuantiFERON-TB Gold (QFT) (Qiagen, Hilden, Ger-
many) which measures produced IFN-γ in whole blood culture [3]. Both
tests use similar Mtb-specific antigens.
Per manufacturer's instructions, QFT results are interpreted as
positive or negative using 0.35 IU/mL as a cut-off but this dichotomy is
subject to debate [4–6]. In studies of repeated QFT testing of healthcare
workers (HCW), results near the cut-off had a high conversion or re-
version rate [5,7–10], and such varying results were mostly attributed
to random assay variation. This has resulted in a zone of uncertainty,
variably named the “borderline zone” or “gray zone”, ranging between
0.20-0.25 and 0.70–1.0 IU/mL [5,7,9,11], and has led to repeated
testing in some settings.
In two previous meta-analyses, the predictive value of IGRA for
development of active tuberculosis was modest [12,13]. In a recent
study, conversion of QFT from less than 0.20 IU/mL to greater than
0.70 IU/mL was associated with the highest incidence of TB disease
[14] and this was proposed as a better definition of conversion. The
authors acknowledged that a proportion of QFT results just below the
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regular cut-off might reflect weak yet Mtb-specific responses but stated
that borderline results “cannot further be teased apart” [14].
In a previous study we provided proof of concept that borderline
results actually include true antigen specific responses, showing that
borderline QFT results (0.15–0.35 IU/mL) occurred in threefold excess
over the number expected based on random variability and that the
presence of various non-IGRA risk factors and parameters of Mtb in-
fection showed a gradient along increasing quantitative QFT results
[15]. The clinical relevance of a distinction between Mtb-specific re-
sponses and test variability on an individual basis will be highest if an
individual is or will become immunocompromised [16–18]. The aim of
the present study was to investigate whether it is possible to determine
which QFT results near the regular cut-off were Mtb antigen-specific
immune responses. We used a large cohort of BCG-unvaccinated con-
tacts from two previous interconnected studies. All contacts were su-
permarket customers in a large-scale contact investigation in the
Netherlands, in whom TST, QFT as well as T-SPOT results had been
performed simultaneously.
By comparing quantitative QFT results with corresponding TST and
T-SPOT results we were able to differentiate between infection and
random variation. In addition, development of active TB was assessed
in a 12-years follow-up in these unique cohorts.
2. Methods
2.1. Study population
Two cohorts of BCG-unvaccinated individuals from previous studies
were used. The combined studies included 829 individuals, of which 78
patients took part in both studies (Fig. 1).
2.1.1. Cohort 1
In 2005, 785 contacts were included during a large contact in-
vestigation after exposure to a supermarket employee with smear-po-
sitive tuberculosis. The study protocol was approved by the ethical
review board of Hospital Diakonessenhuis Utrecht/Zeist, The
Netherlands (protocol 2004.23) and all participants had provided
written informed consent. The results were published in 2007 [19], the
key finding being that both IGRA were more strongly associated with
exposure, expressed as the cumulative shopping time in the super-
market, than the TST.
2.1.2. Cohort 2
As a follow up study of the abovementioned contact investigation,
122 individuals with a positive TST result were followed prospectively
during two years with repeated QFT and T-SPOT. The study protocol
was approved by the ethical review board of the Leiden University
Medical Center (protocol P05.53) and all participants provided written
informed consent. The results were published in 2008, including a table
with all individual follow-up IGRA responses [20]. The results showed
the variable kinetics of IGRA responses which were unaffected by
treatment of LTBI, indicating limited value of IGRA during follow-up.
2.2. Study design
All valid IGRA results in both abovementioned cohorts were eval-
uated to determine whether there was an excess of borderline results (in
this study defined as ≥0.15 and < 0.35 IU/mL) compared to the
corresponding negative range (−0.35 to −0.15 IU/mL). Subsequently,
individuals with a borderline QFT result (in this study defined as≥0.15
and < 0.35 IU/mL) were compared to those with a low-negative
(< 0.15 IU/mL) or a positive result (≥0.35 IU/mL) with respect to
demographic data, exposure risk, T-SPOT and TST results. All data were
extracted from the existing databases from aforementioned studies
[20,21]. From individuals with at least one borderline QFT result
during the two-year IGRA follow-up study, the time course of si-
multaneous, previous or later IGRA responses was evaluated.
2.3. IGRA and interpretation
Both IGRAs (QFT-GIT and T-SPOT.TB) were performed according to
the manufacturer's instructions [22]. QFT-GIT was considered positive
if≥ 0.35 IU/mL. In 2005, a T-SPOT result ≥6 spots was considered
positive according to the package insert [19,20]. However, the package
insert was later changed to a cut-off of ≥8 spots for a positive result,
5–7 spots being labelled as ‘borderline ’, and these new criteria were
used for the present study [23]. Either a TST ≥10mm or a positive T-
SPOT result was interpreted as having a high likelihood of infection
with Mtb.
2.4. Follow-up
From all 829 contacts (785 in cohort 1 and 44 additional contacts in
cohort 2) it was checked in the medical records of the MHS whether
they had developed active TB between 2005 and March 2017. In case of
active TB, the localization of TB, immune status including HIV serology,
culture results and Mtb variable number of tandem repeats (VNTR)
genotype of those with a positive culture were recorded. Due to the
study protocols it was not possible to check for possible active TB di-
agnosed elsewhere.
2.5. Statistical analyses
To compare categorical data, chi-square test or Fishers Exact
Probability test were used. Continuous data were compared using one-
way ANOVA, Mann-Whitney U or Kruskal-Wallis test as appropriate.
Statistical analyses were performed using IBM SPSS Statistics version 23
and GraphPad Prism 7.
3. Results
3.1. Distribution of QFT results
From cohort 1, 704/785 (89.7%) QFT results were negative and 81/
785 (10.3%) were positive. The distribution of quantitative QFT results
Fig. 1. Time line of the study; Abbreviations: TST, tuberculin skin test; IGRA, interferon-gamma release assay.
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is shown in Fig. 2. Of the 704 negative results, ten (1.3%) were between
−0.35 and −0.15 IU/mL; 271 (34.5%) were between −0.15 and 0 IU/
mL; 123 (15.7%) were exactly zero; 266 (33.9%) were between zero
and 0.15 IU/mL; 29 (3.7%) were≥0.15 and ˂0.35 (the latter defined as
borderline results). There was a threefold excess of borderline test re-
sults (n= 29 vs. 10 in the corresponding opposite range between
−0.35 and −0.15 IU/mL, p= 0.0027).
3.2. Comparison between contacts with low-negative, borderline and
positive QFT results
Contacts from cohort 1 with low-negative, borderline or positive
QFT results were compared (Table 1). There were no significant dif-
ferences between the QFT categories with regard to socio-demographic
characteristics, travel to a TB-endemic country or professional risk. A
minority of individuals (23/772, 3.0%) had an impaired immune status,
which was independent of the QFT result. There was a trend towards an
association between the cumulative shopping time and higher QFT
results (p= 0.056). Among contacts with a low-negative, borderline, or
positive QFT result, a positive TST (≥10mm) was found in 24.9%,
62.1% respectively 91.4% (p < 0.0001) and a positive T-SPOT result
in 6.3%, 41.3% respectively 86.4% (p < 0.0001). A similar gradient
was found for TST size, median number of spots in T-SPOT, and the
proportion of contacts with responses to both T-SPOT antigen panels
(Fig. 3). An analogous analysis based on classification of T-SPOT results
as low negative (< 5 spots), borderline (5–7 spots) or positive (≥8
spots) showed similar results, as is shown in Table S1.
3.3. Kinetics
Of the 122 individuals from cohort 2, 17 had at least one borderline
QFT result, of whom four had also been included in cohort 1. Fig. S1
shows the variable kinetics of QFT and T-SPOT in these 17 individuals.
In 6/17 individuals, all repeated QFT were negative, 5/17 converted to
positive, 3/17 reverted from positive to negative and a combination of
conversion and reversion was observed in 3/17 individuals. A positive
T-SPOT result was observed at least once in 11/17 contacts. Of four
contacts with a borderline QFT result during the initial contact in-
vestigation, all had a simultaneous or later positive TST and/or T-SPOT
result. In the remaining 105 persons without any borderline result,
conversion and reversion rates were 1.9% resp. 2.8%.
3.4. Borderline versus low-positive QFT results
Table 2 shows the characteristics of the 29 contacts with a border-
line, and 16 contacts with a low-positive QFT result from cohort 1. Ten
subjects also participated in the follow up study and repeated IGRA
results were available after six, 12 and/or 24 months. A combination of
a TST ≥10mm and a positive T-SPOT result was seen in 10/29 (34.4%)
subjects with a borderline result compared to 12/16 (75%) individuals
with a low-positive result (p= 0.013). At least one earlier or later po-
sitive QFT result was observed in 3/4 (75%) individuals with a bor-
derline result compared to 4/6 (67%) in patients with a low-positive
result. A positive TST and/or a positive T-SPOT result was present in
20/29 (69.0% [95% CI: 52–86%]) contacts with a borderline result and
14/16 (87.5% [95% CI: 71–100%]) contacts with a low-positive QFT
result.
3.5. 12-Year follow-up
During the 12 years since the contact investigation in 2005, active
tuberculosis had been diagnosed in seven contacts (Table 3). Two pa-
tients with active tuberculosis (case 5 and case 6) had been included in
both cohort 1 and 2, the remaining five only in cohort 1. The interval
between QFT testing and time of diagnosis ranged between 0 and 132.5
months. Two patients were diagnosed with active TB during the contact
tracing and both were QFT, T-SPOT and TST positive. Four other con-
tacts who developed TB all had a positive TST, T-SPOT and QFT result
which was just above the cut-off level in two patients. One patient, who
had a negative TST and QFT at time of contact investigation developed
active TB with a different genotype of Mtb compared to the index pa-
tient and was thus probably infected later by another source, possibly
during his work in a prison. None of the contacts were im-
munocompromised.
4. Discussion
Previous reports on borderline QFT results were unable to dis-
criminate between Mtb-specific responses and random test variability.
In order to address this diagnostic gap, the present study evaluated a
large number of BCG-unvaccinated contacts in a Dutch outbreak setting
who were simultaneously tested with TST, QFT and T-SPOT. Based on
simultaneous positive TST and/or a positive T-SPOT result, we con-
cluded that 69% of borderline QFT results just below the regular cut-off
and 88% of low-positive QFT results were probably Mtb-specific re-
sponses, although this can be considered subjective as no true gold
standard for LTBI exists. Two of sixteen contacts with a low-positive
result developed active TB.
The main aim of this study was to investigate borderline QFT results
and the key challenge was how LTBI can be diagnosed independent of
QFT if there is no gold standard available. We reasoned that a TST
≥10mm in BCG-unvaccinated contacts and/or a clear positive T-SPOT
result would indicate a high probability of infection with Mtb, espe-
cially if occurring concurrently. Among contacts with a borderline QFT
result, 62.1% had a positive TST and 41.3% had a positive T-SPOT
result, mostly with a large number of spots and responses to both ESAT-
6 and CFP-10 peptide antigen panels, which effectively excludes
random variability. The gradual increase of the proportion of positive
TST and T-SPOT results in higher QFT categories challenges the di-
chotomous regular cut-off. The reliability of TST and T-SPOT as alter-
native indicators of LTBI needs consideration, however. Both T-SPOT
and TST have a high sensitivity for detecting an infection with Mtb,
while the specificity of T-SPOT is superior [24]. Limitations of the TST
Fig. 2. Distribution of QuantiFERON results. QuantiFERON-TB Gold In-Tube®
(QFT) result below −1.0 IU/mL is depicted as −1.0 (N=1), results higher
than 8.0 IU/mL are depicted as 8.0 (N=10). The number of borderline results
was significantly higher than the number of results within the corresponding
range of minus values (p < 0.0001).
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are inter-observer variability and possible false positive results due to
BCG-vaccination or exposure to non-tuberculous mycobacteria [25,26].
In our study, inter-observer variability was minimal because TST in-
durations were the average of measurements by two independent
readers and a third person made the final reading if the inter-observer
difference exceeded two mm [19]. BCG was not an issue as our study
included only BCG-unvaccinated contacts. In theory, exposure to non-
tuberculous mycobacteria could not be excluded as a source of false
positive TST results but we expect this factor to be minimal in our
setting [27]. Thus, the TST and T-SPOT data allowed us to discriminate
between true Mtb-specific responses and random variation both at the
group and the individual level with fair reliability.
An additional argument in favor of Mtb-specificity of most border-
line QFT results was based on our hypothesis that the distribution of
QFT results in uninfected contacts would be symmetrical relative to
zero. The observed distribution of QFT results, however, was non-
symmetrical with a clear excess of results in the borderline range. In
three previous studies in different settings, a similar nonsymmetrical
distribution was observed [14,15,28]. This consistency supports the
idea of an overlap between QFT responses in Mtb-infected and
Table 1
Characteristics of contacts in cohort 1 by QuantiFERON result.
Characteristic QFT low-negative QFT borderline QFT positive All p value
(< 0.15 IU/mL) (0.15–0.35 IU/mL) (≥0.35 IU/mL)
N=675 N=29 N=81 N=785
Age (y) 43.1 ± 11.4 43.4 ± 10.7 44.1 ± 10.7 43.2 ± 11.3 0.766
range (y) 14.4 to 60.1a 17.9–59.9 18.7–59.8 14.4–60.1a
Sex (female) 389/668 (58.2) 15/29 (51.7) 55/79 (69.6) 459/776 (59.1) 0.106
Immigrant (first generation) 20/666 (3.0) 2/27 (7.4) 1/81 (1.2) 23/774 (3.0) 0.282
Travel to TB-endemic countryb 266/674 (39.5) 14/29 (48.3) 31/81 (38.3) 311/784 (39.7) 0.687
Professional risk 172/648 (26.5) 6/29 (20.7) 18/79 (22.8) 196/756 (25.9) 0.622
Immunocompromised 20/662 (3.0) 1/29 (3.4) 2/81 (2.5) 23/772 (3.0) 0.909
Cumulative shopping time (h) 24.7 ± 25.3 29.4 ± 20.7 31.7 ± 25.4 25.6 ± 25.3 0.056
TST result (mm) 4.5 ± 6.7 11.6 ± 8.4 18.3 ± 5.7 6.17 ± 7.9 < 0.0001
TST category < 0.0001
0–4mm 441/675 (65.3) 7/29 (24.1) 1/81 (1.2) 449/785 (57.2)
5–9mm 66/675 (9.8) 4/29 (13.8) 6/81 (7.4) 76/785 (9.7)
10–14mm 87/675 (12.9) 6/29 (20.7) 6/81 (7.4) 99/785 (12.6)
≥15mm 81/675 (12.0) 12/29 (41.4) 68/81 (84.0) 161/785 (20.5)
T-SPOT.TB result (nr. of spots) 1.7 ± 4.6 14.3 ± 19.6 36.6 ± 36.5 5.9 ± 17.1 < 0.0001
T-SPOT.TB <0.0001
negative (≤4 spots) 583/649 (89.8) 14/29 (48.3) 9/81 (11.1) 606/759 (79.8)
borderline (5–7 spots) 25/649 (3.9) 3/29 (10.3) 2/81 (2.5) 30/759 (4.0)
positive (≥8 spots) 41/649 (6.3) 12/29 (41.3) 70/81 (86.4) 123/759 (16.2)
8-10 spots 12/41 (29.3) 0/12 (0) 2/70 (2.9) 14/123 (11.3)
11-20 spots 24/41 (58.5) 4/12 (33.3) 21/70 (30.0) 49/123 (39.8)
21-50 spots 4/41 (9.8) 6/12 (50.0) 27/70 (38.6) 37/123 (30.1)
≥50 spots 1/41 (2.4) 2/12 (16.7) 20/70 (28.6) 23/123 (18.7)
ESAT-6 and/or CFP-10 positive < 0.0001
ESAT-6 only 3/41 (7.3) 1/12 (8.3) 6/70 (8.6) 10/123 (8.1)
CFP-10 only 36/41 (87.8) 4/12 (33.3) 16/70 (22.9) 56/123 (45.6)
ESAT-6 and CFP-10 both 2/41 (4.9) 7/12 (58.3) 48/70 (68.6) 57/123 (46.3)
Continuous variables are displayed as mean ± SD, categorical values are displayed as numerator over denominator (%).
Abbreviations: QFT, QuantiFERON-TB Gold In-Tube; TST, tuberculin skin test.
a After omission of one contact aged 85.5 y.
b Defined as country with TB incidence ≥50 cases of active tuberculosis/100,000 inhabitants.
Fig. 3. Distribution of tuberculin skin test and T-
SPOT results by QuantiFERON category. Tuberculin
skin test results (TST) (A) and T-SPOT.TB (T-SPOT)
(B) results by QuantiFERON-category. The upper and
lower margins of each rectangle enclose the inter-
quartile range; the middle line represents the median
and the whiskers equal the 5–95% percentile range.
The horizontal dotted line denotes the cut-off (being 8
spot forming units in T-SPOT and 10mm in TST).
Nonparametric comparison of two groups was done
with the Mann-Whitney test, Kruskal-Wallis test was
used to determine differences between the three QFT
groups.
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-uninfected individuals. The relative proportion of Mtb-specific re-
sponses among individuals with a borderline QFT result will vary by
setting, being lower in low-risk populations such as in serial screening
of healthcare workers in a low incidence setting but higher in case of
screening of close contacts or other high risk groups.
Nevertheless, one third of borderline results (9/29) and 12% (2/16)
of low-positive QFT results could not be accounted for by TST or T-
SPOT and most likely reflected test variability. Underlying causes of
these responses could be technical or immunological such as cross-
reactivity to Mycobacterium marinum or M. kansasii [29,30] or im-
munomodulation by microbial products which may induce increased
IFN-γ production and even false-positive results [31]. The proportion of
contacts of cohort 1 with an assumed false positive QFT result was just
2/785 (0.25%) indicating that this is a quantitatively small problem.
While our study showed that borderline QFT results are mostly Mtb-
specific, the question is whether this finding is of clinical relevance. In a
cohort such as described, mostly consisting of immunocompetent con-
tacts, the finding of borderline QFN results is probably of limited
Table 2
Overview and interpretation of contacts with a borderline or low-positive QuantiFERON test result.
Category
QFT
Nr. Sex Age (y) TST (mm) Cumulative
shopping
time (min)
Quantiferon result (IU/mL) T-SPOT resulta (Nr. of spots) Interpretationb
at time of
investigation
at 6 mo at 12mo at 24mo panel A
(ESAT6)
panel B
(CFP10)
maximum
panel A/B
Test result
Borderline 1 M 54 600 0 0.15 0 0 0 neg test variability
(0.15–0.35
IU/mL)
2 F 47 600 0 0.15 0 0 0 neg test variability
3 F 60 2400 0 0.21 0 0 0 neg test variability
4 F 49 2400 0 0.24 0 0 0 neg test variability
5 M 43 1200 0 0.33 0 0 0 neg test variability
6 M 41 960 0 0.16 −4 1 1 neg test variability
7 F 43 N.A. 0 0.28 1 0 1 neg test variability
8 M 55 1200 6 0.22 0 20 20 pos LTBI
9 F 38 2400 6 0.18 4 25 25 pos LTBI
10 M 18 270 8 0.17 3 1 3 neg test variability
11 F 47 2400 8 0.31 7 1 7 borderline test variability
12 F 50 2400 10 0.21 4 5 5 borderline LTBI
13 M 48 2400 10 0.19 14 18 18 pos LTBI
14 F 26 2400 11 0.34 21 9 21 pos LTBI
15 M 32 N.A. 12 0.19 3 2 3 neg LTBI
16 M 33 4800 12 0.21 3 33 33 pos LTBI
17 M 46 2400 13 0.16 19 25 25 pos LTBI
18 M 29 120 16 0.15 N.A. 0.53 0.61 0 1 1 neg LTBI
19 F 56 15 17 0.19 4 3 4 neg LTBI
20c M 46 N.A. 17 0.17 18 5 18 pos LTBI
21 M 57 270 18 0.15 −4 2 2 neg LTBI
22 F 60 1200 18 0.25 1.27 0.67 2.13 28 14 28 pos LTBI
23 F 43 960 18 0.26 24 84 84 pos LTBI
24 F 34 2400 19 0.31 3 4 4 neg LTBI
25 F 39 2400 21 0.2 0.09 0.02 N.A. 0 1 1 neg LTBI
26 M 57 1200 21 0.16 7 7 7 borderline LTBI
27 M 34 1200 23 0.22 0.32 N.A. 0.67 13 27 27 pos LTBI
28 F 37 4800 25 0.25 20 62 62 pos LTBI
29 F 38 2400 26 0.3 5 14 14 pos LTBI
Low
positive
1 F 57 4800 0 0.56 −1 −1 −1 neg test variability
(0.35–0.70
IU/mL)
2 F 58 2400 7 0.46 3 3 3 neg test variability
3 N.A. 59 300 12 0.38 0 0 0 neg LTBI
4 F 28 600 14 0.57 7 6 7 borderline LTBI
5d F 40 2400 15 0.46 13 12 13 pos LTBI
6 M 47 400 15 0.54 4 14 14 pos LTBI
7 M 28 2400 15 0.35 0.65 0.45 0.43 15 15 15 pos LTBI
8 F 45 2400 15 0.43 5 28 28 pos LTBI
9 F 55 2400 17 0.45 0.3 N.A. 0.13 6 13 13 pos LTBI
10 M 42 1200 18 0.56 16 15 16 pos LTBI
11 F 36 1200 20 0.63 N.A. 0.16 0.16 2 9 9 pos LTBI
12d F 39 2400 20 0.38 N.A. N.A. 1.83 16 13 16 pos LTBI
13 F 49 600 20 0.38 4.09 10 1.47 72 77 77 pos LTBI
14 M 54 2400 21 0.39 35 25 35 pos LTBI
15 F 38 N.A. 22 0.66 13 4 13 pos LTBI
16 F 23 2400 25 0.37 3.6 0.85 1.44 7 18 18 pos LTBI
Abbreviations: M, male; F, female; INH, isoniazid; TST, tuberculin skin test; QFT, QuantiFERON-TB Gold In-Tube; N.A., not acquired; LTBI, latent tuberculosis
infection.
All positive test results for TST (≥10 mm), Quantiferon (≥ 0.35 IU/mL) or T-SPOT (according to the more recent cut-off: ≥8 spots) are indicated in bold.
Borderline T-SPOT results (5 to 7 spots) are indicated in italic.
a T-SPOT result at time of contact investigation, available later T-SPOT results are not shown (T-SPOT follow up results of subjects 18, 22, 25 and 27 are shown in
Supplementary Fig. 1).
b Contacts with at least a positive TST (≥10mm) and/or a positive T-SPOT (≥8 spots) were interpreted as having a high likelihood of infection with M.
tuberculosis.
c Immunocompromised.
d Developed active tuberculosis
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clinical significance. While lowering the cut-off has been considered
and discarded for routine use, we think that a borderline QFT result in
patients who are or will be immunocompromised should be regarded as
a significant finding, justifying treatment for LTBI even in the absence
of absolute proof. We recently diagnosed a patient with disseminated
tuberculosis after negative QFT screening before starting infliximab,
but in retrospect the QFT result was 0.22 IU/mL (manuscript sub-
mitted). Although none of the individuals with a borderline QFT result
in our study cohort developed active TB, two of the seven patients who
developed active TB during follow up had QFT results just above the
regular cut-off level indicating that a low positive QFT response is re-
levant. In another study, 19/1664 (1.1%) of individuals with a bor-
derline (defined as 0.2–0.35 IU/mL) compared to 77/28976 (0.3%) in
those with a low-negative results and 70/1992 (3.5%) with a low-po-
sitive QFT result (defined as 0.35–0.99 IU/mL) developed active TB,
most of whom within three months [28]. QFT results near the cut-off
thus are not a ‘safe zone’ regarding the risk of active TB, although the
risk seems to be directly related to the quantitative QFT result [3,14].
Follow-up individual IGRA results in our study were variable, as
previously published [20]. The observed conversion rate was similar to
that of a previous study in which one-fifth of results just below the cut-
off converted [32]. Retesting may give a different and more ‘con-
venient’ test result but our follow up data show that QFT reversion does
not exclude infection with Mtb, although it probably reflects a lower
risk of progression. Based on just one borderline QFT result it is not
possible to make a reliable interpretation without additional tests,
which are justified if it is important to obtain a higher level of certainty.
Borderline QFT results just below the cut-off are found in just a small
minority of tested individuals, varying between 2.4 and 4.2%
[15,28,32]. In practice, other information such as the clinical setting, a
history of exposure or signs of LTBI on a chest X-ray contributes to the
evaluation and clinical decision making. Banaei and Pai have proposed
to define a formal borderline range of QFT results [33]. However, if it is
clinically important, the TST and T-SPOT may help to obtain more
certainty unless the patient is immunocompromised and immune-based
tests are therefore less sensitive [17,34–36].
Among the limitations of our study are the retrospective design and
the low number of borderline and low-positive results. The number of
contacts who developed active tuberculosis was low and the study
therefore lacked power to evaluate the risk among contacts with a
borderline QFT results. Due to the study protocol it was not possible to
retrieve the treatment decision for the study participants, which affects
the individual risk of development of active TB. The main strength of
our study was the availability of TST, QFT as well as T-SPOT results in a
large homogeneous cohort of contacts, allowing the distinction between
Mtb infection and test variability. We think that future studies of bor-
derline QFT results will gain persuasiveness if the distinction between
Mtb infection and test variability will be made based on additional TST
and/or T-SPOT data. IFN-γ being just one cytokine, the potential of QFT
might be augmented by measurement of alternative cytokines or other
biomarkers [37–39].
Since 2015, the QuantiFERON-TB Gold Plus (QFT Plus) has replaced
the previous In-Tube version. QFT Plus uses peptides of the same an-
tigens ESAT-6 and CFP-10 but lacks TB7.7, while a second antigen-
specific tube in addition contains shorter peptides of CFP-10 to stimu-
late CD8 T-cells [40]. The test was designed for higher sensitivity for
active TB or recent infection but, thus far, the sensitivity of QFT Plus
was not different from that of QFT [41–43]. A formal analysis of bor-
derline QFT Plus result has not yet been published. However, a study
among low risk health-care workers found that most participants with a
discordance between QFT and the TB1 and/or TB2 tube of QFT Plus had
a response between 0.2 and 0.7 IU/mL in one or both assays, thus in-
cluding borderline responses [44]. This is another argument in favor of
the idea that borderline results are mostly true antigen-specific re-
sponses, with the positive result in the other format as validation.
5. Conclusion
In conclusion, two-third of borderline QFT results and 88% of low-
positive QFT results in tuberculosis contacts were Mtb-specific as cor-
roborated by TST and T-SPOT data. Active tuberculosis was diagnosed
in 12.5% of contacts with a low-positive QFT. We think that future
studies of borderline QFT responses should address the discrimination
between Mtb-specific responses and test variability. The clinical re-
levance, however, will be most distinct in patients who are or will be
immunocompromised.
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